Latest news with #Nepexto
Business Standard
7 days ago
- Business
- Business Standard
Biocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in Australia
Biocon advanced 1.34% to Rs 392.25 after the company said that Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia. Nepexto will be promoted by Generic Health, BBLs local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in Australia. Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is working towards expanding Nepexto into new markets worldwide and further strengthen the companys immunology offering. Biocon Biologics, a subsidiary of Biocon, is a fully integrated, global biosimilars company. It has commercialized various biosimilars in key emerging markets and advanced markets. It has a pipeline of numerous biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The companys consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24.
Economic Times
7 days ago
- Business
- Economic Times
Biocon Biologics launches product for autoimmune diseases in Australia
Biocon on Wednesday said its subsidiary Biocon Biologics has launched a product for the treatment of autoimmune diseases like rheumatoid arthritis, in the Australian market. The company has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia, the company said in a regulatory filing. Nepexto will be promoted by Generic Health, a local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in that country, it added. Etanercept is a fusion-protein that inhibits tumour necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Since receiving EU marketing authorisation in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen its immunology offering, it said. Shares of Biocon were trading 1.72 per cent up at Rs 393.70 apiece on BSE.
Time of India
7 days ago
- Business
- Time of India
Biocon Biologics launches product for autoimmune diseases in Australia
Biocon on Wednesday said its subsidiary Biocon Biologics has launched a product for the treatment of autoimmune diseases like rheumatoid arthritis, in the Australian market. The company has launched Nepexto , a biosimilar to the reference product Enbrel (Etanercept), in Australia, the company said in a regulatory filing. Explore courses from Top Institutes in Please select course: Select a Course Category Leadership Digital Marketing Operations Management Artificial Intelligence Degree Product Management Data Analytics Data Science Design Thinking Healthcare healthcare CXO Public Policy MCA PGDM others MBA Finance Management Cybersecurity Technology Others Data Science Project Management Skills you'll gain: Duration: 18 Weeks 109820388 Strategic Marketing for Leaders: Leveraging AI for Growth Starts on undefined Get Details Skills you'll gain: Duration: 12 Weeks IIM Kozhikode CERT-IIMK EPIS Async India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months IIM Indore Executive Programme in Business Management Starts on undefined Get Details Skills you'll gain: Duration: 11 Months IIM Lucknow CERT-IIML SLP India Starts on undefined Get Details Skills you'll gain: Duration: 12 Months IIM Kozhikode SEPO - IIMK CEO Programme India Starts on undefined Get Details Skills you'll gain: Duration: 22 Weeks Indian School of Business SEPO - ISB Venture Capital & Private Equity India Starts on undefined Get Details Skills you'll gain: Financial Accounting & Analysis Financial Instruments & Markets Corporate Finance & Valuation Investment Management & Banking Duration: 12 Months IIM Kozhikode IIMK Professional Certificate in Financial Analysis and Financial Management Starts on Mar 30, 2024 Get Details Skills you'll gain: Strategic Thinking & Planning Competitive Advantage & Market Positioning Strategic Leadership & Decision-Making Change Management & Organizational Transformation Duration: 1 Year IIM Kozhikode IIMK Advanced Strategic Management Programme Starts on Mar 30, 2024 Get Details Skills you'll gain: Opportunities & Outlining Plans to use AI & ML Applying Data-Driven Business Innovation Best Practices Changing Culture to Integrate AI-Enabled Technologies Ethics, Privacy and Regulations in AI & ML Duration: 20 Weeks Indian School of Business ISB Leadership in AI Starts on May 14, 2024 Get Details Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK-Women Leadership Programme INDIA Starts on undefined Get Details Skills you'll gain: Duration: 12 Months IIM Kozhikode Senior Management Programme Starts on undefined Get Details Skills you'll gain: Critical Thinking & Decision-Making Skills Power of Emerging Technologies Innovation and Drive Organizational Change Fostering a Culture of Innovation Duration: 9 Months MIT xPRO MIT Technology Leadership and Innovation Starts on May 14, 2024 Get Details Skills you'll gain: Duration: 12 Months IIM Kozhikode Advanced Strategic Management Programme Starts on undefined Get Details Nepexto will be promoted by Generic Health, a local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in that country, it added. Etanercept is a fusion-protein that inhibits tumour necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Since receiving EU marketing authorisation in 2020, Nepexto has earned broad adoption across Europe. Live Events Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen its immunology offering, it said. Shares of Biocon were trading 1.72 per cent up at Rs 393.70 apiece on BSE.
News18
7 days ago
- Business
- News18
Biocon Biologics launches product for autoimmune diseases in Australia
Agency: PTI Last Updated: New Delhi, Jul 23 (PTI) Biocon on Wednesday said its subsidiary Biocon Biologics has launched a product for the treatment of autoimmune diseases like rheumatoid arthritis, in the Australian market. The company has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia, the company said in a regulatory filing. Nepexto will be promoted by Generic Health, a local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in that country, it added. Etanercept is a fusion-protein that inhibits tumour necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Since receiving EU marketing authorisation in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen its immunology offering, it said. Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Standard
7 days ago
- Business
- Business Standard
Biocon Biologics launches biosimilar
Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia. Nepexto will be promoted by Generic Health, its local partner and a leading provider of high-quality generic prescription, injectable and over-the counter medicines, to expand access to patients in Australia. Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen the company's immunology offering.
